(Reuters) -AstraZeneca said on Monday its precision drug Datroway improved overall survival and progression free survival in patients with an advanced form of breast cancer versus chemotherapy in a trial when given early during treatment.
The treatment, which is being developed with partner Daiichi Sankyo, was given as first-line therapy in the trial for patients with metastatic triple-negative breast cancer for whom immunotherapy was not an option, AstraZeneca said.
(Reporting by Pushkala Aripaka in Bengaluru; Editing by Nivedita Bhattacharjee)
Brought to you by www.srnnews.com
